Cancer Screening Test Articles & Analysis
18 news found
The lung cancer screening demonstration project led by Dr Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec-Université Laval – IUCPQ-UL) is intended to combine BioMark’s metabolomics liquid biopsy test with radiomics and genetics biomarkers ...
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland’s Euformatics and Hungary’s Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven leading central European hospitals*, represented ...
Poster title: “Quantification of Beta-Hydroxybutyric acid and Tryptophan in plasma as metabolic biomarkers of cancer using the LDTD-MS/MS technique”. The poster attracted interest from many potential companies in the clinical lab space on the use of this novel integrated technology for cancer screening application. ...
The peer-reviewed article published in the journal Frontiers in Oncology (article), shows that the prostate cancer test based on CTC harvested with the ISET® technology and identified by the Immuno-Cytochemistry (ICC) PSA marker has an estimated positive-predictive-value (PPV) of 99% and negative-predictive-value (NPV) of 97%, providing a more reliable ...
The conference will be a remarkable occasion for BioMark to expand its global visibility and cultivate new collaborations with key opinion leaders and institutions as we are planning to introduce our lung cancer screening test early next year.” says Rashid Bux, CEO of BioMark. ...
INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is ...
During the second quarter the Company was notified by Novitas, it’s CME intermediary, that pricing for one of its flagship thyroid cancer screening tests was reduced by 70% retroactive to the beginning of 2022. ...
Quantitative Fecal Immunochemical Tests (FIT) are recommended for colorectal cancer population screenings. ...
Recommended screening tests only cover five cancer types in the U.S.: breast, colon, cervical, prostate, and, in high-risk smokers, lung. More than 70 percent of cancer deaths are from cancers that lack recommended early detection screening. ...
CT About the Oncotype DX and Oncotype MAP™ Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence ...
About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimize cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score ...
With NYSDOH approval, Galleri is now available to residents in the state of New York by prescription to complement existing single cancer screening tests. The standard set by New York State represents one of the most rigorous levels of validation required for laboratory developed tests. ...
New results from the OMICS study, the company's prospective, international, multi-center study, show Universal DX's blood test can detect colorectal advanced adenomas at 55% sensitivity and 90% specificity, which exceeds currently available non-invasive tests for colorectal cancer screening 80% of sporadic colorectal ...
New results from the OMICS study, which will be presented atASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity / 97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening Early detection ...
About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score ...
Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical ...
Galleri is expected to launch commercially in 2021 as a multi-cancer, laboratory developed test for early cancer detection from blood. GRAIL plans to follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer patients. ...
We are excited that companies and organizations across the country are joining us in celebrating Choose You Day and giving those who drive their companies" success an opportunity to put their health first," said Terry Music, American Cancer Society chief mission delivery officer. Choose You Day celebrates employees putting their health first and helps raise awareness of, and ...